Skip to main content
SpringerLink
Log in

Overview of Toxicity Outcomes with Prostate SBRT and Comparison to Other Treatment Interventions (Urinary, Rectal and Sexual Outcomes)

  • Chapter
  • First Online:
Stereotactic Radiosurgery for Prostate Cancer

  • 607 Accesses

Abstract

Prostate cancer is the most common cancer diagnosis amongst adult males in the United States, with approximately 160,000 new diagnoses per year in the United States. Treatment of this disease may be associated with genitourinary, gastrointestinal, and sexual adverse effects. Stereotactic body radiation therapy (SBRT) has recently gained acceptance as an effective treatment modality, although concerns have been voiced over a potentially increased risk of toxicity given the high dose-per-fraction regimens employed. Fortunately, a wealth patient-reported outcome (PRO) data, in addition to standard physician-scored toxicity, is available from single and multi-institutional reports. This chapter will review the adverse effects that have been reported following SBRT, provide guidelines for prevention and management of symptoms, and compare these outcomes with those achieved by other treatment methods.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    Article  PubMed  Google Scholar 

  2. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.

    Article  PubMed  Google Scholar 

  3. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol R Coll Radiol G B. 1991;3(3):127–32.

    Article  CAS  Google Scholar 

  5. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(1):236–46.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Repka MC, Guleria S, Cyr RA, Yung TM, Koneru H, Chen LN, et al. Acute urinary morbidity following stereotactic body radiation therapy for prostate cancer with prophylactic alpha-adrenergic antagonist and urethral dose reduction. Front Oncol. 2016;6:122.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Henderson A, Ismail AKA, Cunningham M, Aldridge S, Loverock L, Langley SEM, et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol R Coll Radiol G B. 2004;16(2):95–104.

    Article  CAS  Google Scholar 

  8. Van Gellekom MPR, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys. 2005;63(3):772–80.

    Article  PubMed  Google Scholar 

  9. Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2004;73(1):33–8.

    Article  Google Scholar 

  10. Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol. 2008;179(1):141–5. discussion 146

    Article  PubMed  Google Scholar 

  11. Meier R, Beckman A, Henning G, Mohideen N, Woodhouse SA, Cotrutz C, et al. Five-year outcomes from a multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol. 2016;96(2):S33–4.

    Article  Google Scholar 

  12. Tree AC, Ostler P, Hoskin P, Dankulchai P, Nariyangadu P, Hughes RJ, et al. Prostate stereotactic body radiotherapy—first UK experience. Clin Oncol R Coll Radiol G B. 2014;26(12):757–61.

    Article  CAS  Google Scholar 

  13. Rana Z, Cyr RA, Chen LN, Kim BS, Moures RA, Yung TM, et al. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer. Front Oncol [Internet]. 2014;4: 290. Available from: http://journal.frontiersin.org/article/10.3389/fonc.2014.00290/abstract. Cited 19 Feb 2016.

  14. Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–90.

    Article  PubMed  Google Scholar 

  15. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Danner M, Hung M-Y, Yung TM, Ayoob M, Lei S, Collins BT, et al. Utilization of patient-reported outcomes to guide symptom management during stereotactic body radiation therapy for clinically localized prostate cancer. Front Oncol. 2017;7:227.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Repka MC, Kole TP, Lee J, Wu B, Lei S, Yung T, et al. Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer. Acta Oncol Stockh Swed. 2017;56(8):1136–8.

    Article  Google Scholar 

  19. Locke J, Ellis W, Wallner K, Cavanagh W, Blasko J. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. Int J Radiat Oncol Biol Phys. 2002;52(3):712–9.

    Article  PubMed  Google Scholar 

  20. Qi XS, Wang JP, Gomez CL, Shao W, Xu X, King C, et al. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;121(1):113–7.

    Article  Google Scholar 

  21. Janowski E, Chen LN, Kim JS, Lei S, Suy S, Collins B, et al. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3). Radiat Oncol Lond Engl. 2014;9:241.

    Article  Google Scholar 

  22. Hathout L, Folkert MR, Kollmeier MA, Yamada Y, Cohen GN, Zelefsky MJ. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning. Int J Radiat Oncol Biol Phys. 2014;90(2):312–9.

    Article  PubMed  PubMed Central  Google Scholar 

  23. King CR, Collins S, Fuller D, Wang P-C, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87(5):939–45.

    Article  PubMed  Google Scholar 

  24. Bhattasali O, Chen LN, Woo J, Park J-W, Kim JS, Moures R, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol Lond Engl. 2014;9:52.

    Article  Google Scholar 

  25. Arscott WT, Chen LN, Wilson N, Bhagat A, Kim JS, Moures RA, et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol Lond Engl. 2014;9:163.

    Article  Google Scholar 

  26. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;70(5):1588–97.

    Article  PubMed  Google Scholar 

  27. Fuller DB, Naitoh J, Mardirossian G. Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations. Front Oncol. 2014;4:321.

    PubMed  PubMed Central  Google Scholar 

  28. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol Lond Engl. 2013;8:58.

    Article  Google Scholar 

  29. Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015;116(2):179–84.

    Article  Google Scholar 

  30. Woo JA, Chen LN, Bhagat A, Oermann EK, Kim JS, Moures R, et al. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. Front Oncol. 2014;4:122.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Keyes M, Miller S, Moravan V, Pickles T, Liu M, Spadinger I, et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys. 2009;75(3):649–55.

    Article  PubMed  Google Scholar 

  32. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56(4):1085–92.

    Article  PubMed  Google Scholar 

  33. Kole TP, Tong M, Wu B, Lei S, Obayomi-Davies O, Chen LN, et al. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Acta Oncol Stockh Swed. 2016;55(1):52–8.

    Article  CAS  Google Scholar 

  34. Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschöld P, Oh JH, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):339–44.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, et al. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015;5(5):e465–72.

    Article  PubMed  Google Scholar 

  36. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, et al. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017;123(9):1635–42.

    Article  CAS  PubMed  Google Scholar 

  37. Gurka MK, Chen LN, Bhagat A, Moures R, Kim JS, Yung T, et al. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol Lond Engl. 2015;10:44.

    Article  Google Scholar 

  38. van der Molen AJ, Hovius MC. Hematuria: a problem-based imaging algorithm illustrating the recent Dutch guidelines on hematuria. AJR Am J Roentgenol. 2012;198(6):1256–65.

    Article  PubMed  Google Scholar 

  39. Kataria S, Chew J, Lei S, Ayoob MJ, Danner M, Yung T, et al. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with a high international prostate symptom score (IPSS > 15). Int J Radiat Oncol Biol Phys. 2017;99(2):E538–9.

    Article  Google Scholar 

  40. Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I-K, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol Lond Engl. 2013;8:84.

    Article  Google Scholar 

  41. Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, et al. PATRIOT trial: randomized phase 2 study of prostate stereotactic body radiation therapy comparing 11 versus 29 days overall treatment time. Int J Radiat Oncol Biol Phys. 2015;93(3):S198.

    Article  Google Scholar 

  42. Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, et al. Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: a report on 3-year toxicity. Front Oncol. 2017;7:5.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125–9.

    Article  PubMed  Google Scholar 

  44. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013;87(5):932–8.

    Article  PubMed  Google Scholar 

  45. Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971–7.

    Article  PubMed  Google Scholar 

  46. Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–85.

    Article  PubMed  Google Scholar 

  47. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877–82.

    Article  PubMed  Google Scholar 

  48. Khor R, Duchesne G, Tai K-H, Foroudi F, Chander S, Van Dyk S, et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):679–85.

    Article  PubMed  Google Scholar 

  49. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;103(2):217–22.

    Article  Google Scholar 

  50. Hsu I-C, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010;78(3):751–8.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):286–95.

    Article  PubMed  Google Scholar 

  52. Katz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol Lond Engl. 2014;9:1.

    Article  Google Scholar 

  53. Lin Y-W, Lin L-C, Lin K-L. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer. Front Oncol. 2014;4:278.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol Lond Engl. 2016;11:8.

    Article  Google Scholar 

  55. Hamstra DA, Conlon ASC, Daignault S, Dunn RL, Sandler HM, Hembroff AL, et al. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013;86(3):546–53.

    Article  PubMed  Google Scholar 

  56. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, et al. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;121(2):294–8.

    Article  Google Scholar 

  57. Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(12):1195–201.

    Article  Google Scholar 

  58. Collins SP, Suy S, Chen LN, Collins BT, Lynch J, Dritschilo A. Late urinary symptom flare after prostate stereotactic body radiation therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(30):3451–2.

    Article  Google Scholar 

  59. Chan EK, Keyes M, Pickles T, Lapointe V, Spadinger I, McKenzie M, et al. Decline in acute urinary toxicity: a long-term study in 2011 patients with prostate brachytherapy within a provincial institution. Brachytherapy. 2014;13(1):46–52.

    Article  PubMed  Google Scholar 

  60. Sheets NC, Goldin GH, Meyer A-M, Wu Y, Chang Y, Stürmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Paydar I, Cyr RA, Yung TM, Lei S, Collins BT, Chen LN, et al. Proctitis 1 week after stereotactic body radiation therapy for prostate cancer: implications for clinical trial design. Front Oncol. 2016;6:167.

    PubMed  PubMed Central  Google Scholar 

  62. Sood S, Ju AW, Wang H, Lei S, Uhm S, Zhang G, et al. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol Lond Engl. 2013;8:197.

    Article  Google Scholar 

  63. Macias VA, Blanco ML, Barrera I, Garcia R. A phase II study of stereotactic body radiation therapy for low-intermediate-high-risk prostate cancer using helical tomotherapy: dose-volumetric parameters predicting early toxicity. Front Oncol. 2014;4:336.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Kole TP, Repka MC, Wu B, Lei S, Suy S, Dritschilo A, et al. Dosimetric analysis of predictors of acute bowel toxicity after prostate SBRT (12th International Stereotactic Radiosurgery Society Congress). J Radiosurg SBRT. 2015;3(Suppl 1):1–237.

    Google Scholar 

  65. Ju AW, Wang H, Oermann EK, Sherer BA, Uhm S, Chen VJ, et al. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol Lond Engl. 2013;8:30.

    Article  Google Scholar 

  66. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67(4):1099–105.

    Article  PubMed  Google Scholar 

  67. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol Lond Engl. 2011;6:3.

    Article  Google Scholar 

  68. Musunuru HB, Davidson M, Cheung P, Vesprini D, Liu S, Chung H, et al. Predictive parameters of symptomatic hematochezia following 5-fraction gantry-based SABR in prostate cancer. Int J Radiat Oncol Biol Phys. 2016;94(5):1043–51.

    Article  PubMed  Google Scholar 

  69. Kim DWN, Straka C, Cho LC, Timmerman RD. Stereotactic body radiation therapy for prostate cancer: review of experience of a multicenter phase I/II dose-escalation study. Front Oncol. 2014;4:319.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Kim DWN, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1–2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89(3):509–17.

    Article  PubMed  Google Scholar 

  71. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043–8.

    Article  PubMed  Google Scholar 

  72. Kataria S, Hong RL, McRae D, Cernica G, Foust M, Nasr NM. The rectal dosimetric effects of perirectal hydrogel spacers in men undergoing prostate stereotactic body radiation therapy (SBRT). Int J Radiat Oncol. 2017;99(2, Supplement):E676.

    Article  Google Scholar 

  73. Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, et al. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Med Dosim Off J Am Assoc Med Dosim. 2017;42(4):341–7.

    Google Scholar 

  74. Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2):444–53.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Walsh PC, Schlegel PN. Radical pelvic surgery with preservation of sexual function. Ann Surg. 1988;208(4):391–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. King CR, Lo A, Kapp DS. Testicular dose from prostate CyberKnife: a cautionary note. Int J Radiat Oncol. 2009;73(2):636–7.

    Article  Google Scholar 

  77. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.

    Article  CAS  PubMed  Google Scholar 

  78. Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, et al. Potency preservation following stereotactic body radiation therapy for prostate cancer. Radiat Oncol Lond Engl. 2013;8:256.

    Article  Google Scholar 

  79. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(4):1063–8.

    Article  PubMed  Google Scholar 

  80. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, et al. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2017;121:61–8.

    Article  PubMed  Google Scholar 

  81. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2010;78(2):442–8.

    Article  PubMed  Google Scholar 

  82. Spratt DE, Lee JY, Dess RT, Narayana V, Evans C, Liss A, et al. Vessel-sparing radiotherapy for localized prostate cancer to preserve erectile function: a single-arm phase 2 trial. Eur Urol. 2017;72(4):617–24.

    Article  PubMed  Google Scholar 

  83. Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol OncolJ Hematol Oncol. 2011;4:12.

    Article  CAS  Google Scholar 

  84. Kole TP, Chen LN, Obayomi-Davies O, Kim JS, Lei S, Suy S, et al. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer. Acta Oncol Stockh Swed. 2015;54(6):832–8.

    Article  CAS  Google Scholar 

  85. Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, et al. Patient reported sexual aid utilization and efficacy following radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2018;101(2):376–86. Available from: http://www.redjournal.org/article/S0360-3016(18)30127-5/abstract. Cited 23 Jan 2018

    Article  PubMed  Google Scholar 

  86. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41.

    Article  CAS  PubMed  Google Scholar 

  88. Roach M, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35(5):1011–8.

    Article  PubMed  Google Scholar 

  89. Paydar I, Kim BS, Cyr RA, Rashid H, Anjum A, Yung TM, et al. Urethrogram-directed stereotactic body radiation therapy for clinically localized prostate cancer in patients with contraindications to magnetic resonance imaging. Front Oncol. 2015;5:194.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163(2):496–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Medicine, Georgetown University Hospital, Washington DC, USA

    Michael C. Repka, Simeng Suy, Shaan K. Kataria, Ima Paydar, Brian T. Collins, Jonathan W. Lischalk & Sean P. Collins

  2. Department of Radiation Oncology, The Valley Health Hospital, Ridgewood, NJ, USA

    Thomas P. Kole

  3. Precision Radiation Oncology, Crozer Chester Medical Center, Upland, PA, USA

    Olusola Obayomi-Davies

Authors
  1. Michael C. Repka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simeng Suy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shaan K. Kataria
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas P. Kole
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ima Paydar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brian T. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jonathan W. Lischalk
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olusola Obayomi-Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sean P. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean P. Collins .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

    Michael J. Zelefsky

Ethics declarations

Sean P. Collins is a Clinical Consultant for Accuray.

Role of Funding Source

No funding source.

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Repka, M.C. et al. (2019). Overview of Toxicity Outcomes with Prostate SBRT and Comparison to Other Treatment Interventions (Urinary, Rectal and Sexual Outcomes). In: Zelefsky, M. (eds) Stereotactic Radiosurgery for Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-92453-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92453-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92452-6

  • Online ISBN: 978-3-319-92453-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation